Close Menu

NEW YORK — Diagnostics company Zora Biosciences said on Monday it has signed a non-exclusive license agreement for its ceramide biomarker technology with Quest Diagnostics.

Quest plans to develop a test using Espoo, Finland-based Zora's ceramide technology for identifying patients at risk of cardiovascular conditions and death. Secaucus, New Jersey-based Quest said it aims to begin offering the test through its Cardiometabolic Center of Excellence at Cleveland HeartLab as soon as next year.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Sponsored by

Join Dr. Heather Fehling, Chief Scientific Officer at Clinical Reference Labs (CRL), as she provides some insights regarding the future applications of PCR testing.

Sponsored by

Amid the COVID-19 pandemic, hospitals and intensive care units around the world have been overwhelmed by unprecedented levels of demand. 

Sponsored by

This webinar will present the details of a COVID-19 saliva screening program that has been implemented at more than 90 different colleges, universities, private schools, and nursing homes across New York state.